SFC / Shutterstock.com
In light of the US Supreme Court’s ruling in Akamai v Limelight, Marsha Rose Gillentine, Rebecca Hammond and Robert Millonig suggest drafting strategies for personalised medicine patents to avoid the ‘divided infringement’ pitfalls.
If you have already subscribed please login.
If you have any technical issues please email tech support.
patents; pharmaceuticals; Akamai v Limelight; personalised medicine
